newsfilter
← Latest News
ClinicalTrials.gov·

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) - NCT04939610

Determine the recommended Phase 2 dose of 177Lu-FAP-2286 (Phase 1), Objective response rate (ORR) (Phase 2), Radiation dosimetry of 177Lu-FAP-2286 (Phase 1), (and 9 more...)